 IELSG 29 |
A retrospective study on primary bone marrow lymphoma (M. Rozman, A. Martínez-Pozo, C. Agostinelli, K. M. Hebeda, E. Matutes, M. Ponzoni, A. Ferreri, C. Campidelli, A. López-Guillermo, S. Pileri, E. Campo) 28 patients Lymphomas detected exclusively in the bone marrow, after excluding classically leukemic lymphomas, are rare. In order to assess whether or not primary bone marrow lymphoma (PBML) could be considered as a real entity among extranodal lymphomas, a retrospective analysis is ongoing. The definition of PBML comprised the following criteria: 1) isolated involvement of bone marrow (with or without peripheral blood) 2) no evidence of extra-marrow involvement on imaging studies 3) no evidence of splenic infiltration 4) absence of localized bone tumours 5) exclusion of lymphoma subtypes primarily affecting bone marrow, such as SLL/CLL, lymphoplasmacytic, splenic marginal zone, Burkitt's lymphoma, ALL and lymphoblastic lymphomas. For further information contact: Maria Rozman, Barcelona, Spain Maurilio Ponzoni, Milan, Italy EAHP 2008: poster presentation Original article: Am J Surg Pathol 2012 Feb; 36(2): 296–304 |
| ielsg | |
 IELSG 27 |
A Clinico-pathological phase II study with translational elements to investigate the possible infective causes of MALT lymphoma of the ocular adnexa with particular reference to Chlamydia species and the effects of treatment with tetracycline (Study Chairs: Andrés J. M. Ferreri, Milan, Italy, John Radford, Manchester, UK) 54 patients The development of ocular adnexal MALT lymphoma is frequently associated with chronic conjunctivitis, a well recognised cause of which is infection by Chlamydia. Recent studies from northern Italy provided sound evidence for an association between C. psittaci infection and ocular adnexal MALT lymphoma but this finding was not confirmed by studies conducted in other geographic areas. The purpose of this novel IELSG study is to further investigate this relationship and explore the implications for treatment. This study will address the geographic variability of the association between Chlamidya psittaci infection and ocular adnexa lymphoma and will explore the utility of a first line therapy of ocular adnexal MALT lymphoma with antibiotics alone, attempting to correlate the treatment response to molecular genetic findings. Lugano Conference on Malignant Lymphoma 2011: poster presentation ASH 2011: oral presentation |
| ielsg | |
 IELSG 26 |
Clinico-pathologic study of primary mediastinal B-cell lymphoma (Clinical Trial coordinators: P.W.M. Johnson, Southampton, UK, E. Zucca, Bellinzona, Switzerland, P.L. Zinzani, Bologna, Italy, M. Martelli, Roma, Italy, A. Lopez-Guillermo, Barcelona, Spain) 125 patients This prospective multi-centre cohort study has been designed to investigate the diagnostic and prognostic utility of PET scan in primary mediastinal lymphoma. Aims of the study are the determination of response rate on PET scanning following initial chemo-immunotherapy and a systematic analysis of the phenotype and molecular characteristics of Primary Mediastinal Large B-cell Lymphoma. Patients has been enrolled on the basis of the clinical and pathologic characteristics of their lymphoma. Central review of all pathology is carried out, with storage of fresh frozen biopsy material wherever possible. PET scans has been performed at the start of chemotherapy and at its conclusion, with central review of the images for quality control. Interim (mid-treatment) PET scans are permitted according to normal practice in each centre, but will not be reviewed centrally. Patients have received one of the standard chemo-immunotherapy protocols currently in use for diffuse large B-cell lymphoma (i.e., R-CHOP-21, R-CHOP-14,R-MACOP-B, R-VACOP-B, R-ACVBP). Consolidation radiotherapy to the mediastinum has been carried out according to the local protocol of the treating centre. Lugano Conference on Malignant Lymphoma 2011: oral presentation |
| ielsg | |
 IELSG 25 |
Phase II Study of VELCADE in patients with extranodal marginal zone B-cell lymphoma of MALT-type pretreated with prior systemic therapy (Chairperson: Franco Cavalli, Bellinzona, Switzerland) Open only at some selected centres 32 patients This phase II study investigates the activity and safety of Bortezomib in MALT lymphoma ASH 2007: poster presentation Lugano Conference on Malignant Lymphoma 2008: poster presentation EHA 2009: oral presentation Original article: Annals of Oncology 2011; 22(3): 689-695 |
| ielsg | |
 IELSG 24 |
A Phase I Study of Intrathecal Rituximab in Patients with Lymphomatous Meningitis (Chairperson: Annarita Conconi, Novara, Italy. Co-chairmen: Andrés J. M. Ferreri, Milan, Italy, Franco Cavalli, Bellinzona, Switzerland) The study was closed because of poor accrual |
| ielsg | |
 IELSG 23 |
A retrospective evaluation of primary head and neck lymphoma (Chairperson: Sergio Cortelazzo, Bergamo, Italy, Gianluca Gaidano, Novara, Italy) 657 patients Aim of the study is to collect the largest possible series of head and neck non-Hodgkin's lymphomas treated in the last 10 years, in order to clarify the clinico-pathological features of these entities. Diagnostic material will be also collected in order to characterize their biological features. EHA 2005: oral presentation SIE 2005: oral presentation Lugano Conference on Malignant Lymphoma 2005: abstract presentation ASH 2005: poster presentation EHA 2007: oral presentation ASH 2007: poster presentation EHA 2008: poster presentation SIE 2009: poster presentation Original article: Leukemia and Lymphoma 2011 May; 52(5): 823-832 |
| ielsg | |
 IELSG 22 |
Gastric irradiation for MALT lymphoma: a retrospective study (Principal investigators: Andrew Wirth, John Seymour, Melbourne, Australia, Mary Gospodarowicz, Toronto, Canada, Joachim Yahalom, New York, USA, Emanuele Zucca, Bellinzona, Switzerland) 143 patients This is a multi-centre retrospective review of patients treated with gastric radiation for gastric MALT lymphoma from 1980 through 2002. Aim of the study is to assess local control, survival, late toxicity and patterns of failure. The impact of radiotherapy dose and volume and the impact of tumour characteristics on outcome will also be assessed. |
| ielsg | |
 IELSG 21 |
Salvage therapy with Idarubicin in immunocompetent patients with relapsed or refractory primary central nervous system lymphomas (Study Chairman: Andrés J. M. Ferreri, Milan, Italy) The study was closed because of slow accrual Active salvage therapy may improve survival even in the poor-prognosis subset of relapsing PCNSL patients. However, their second-line therapy is not well defined. Idarubicin is an anthracycline with documented activity in leukemia and lymphoma. Its most active metabolite, idarubicinol passes the BBB and can be detected at therapeutic concentration of standard dose idarubicin. |
| ielsg | |
 IELSG 20 |
Randomized phase II trial on primary chemotherapy with high-dose methotrexate, alone or associated with high-dose cytarabine, followed by response-and age-tailored radiotherapy for immunocompetent patients with newly diagnosed primary central nervous system lymphoma (Study Chairman: Andrés J. M. Ferreri, Milan, Italy) 79 patients This is a multicentre open label randomized phase II trial was aimed to compare the antitumor activity of the sole high-dose methotrexate with the combination of high-dose methotrexate and high-dose cytarabine as primary chemotherapy (max. four courses). In both study arms, at the end of the chemotherapy program, responding patients had WBRT but in patients older than 60 years radiotherapy was not mandatory (at investigator's discretion). Lugano Conference on Malignant Lymphoma 2008: oral presentation EHA 2008: oral presentation ASH 2008: oral presentation Original article: The Lancet 2009 October; 374: 1512-20 Original article: British Journal of Cancer 2010; 102: 673-677 |
| ielsg | |
 IELSG 19 |
Multicenter randomized trial of chlorambucil versus chlorambucil plus rituximab versus rituximab alone in extranodal marginal zone B-cell lymphoma of mucosa associated lymphoid tissue (MALT lymphoma) (Chairpersons: Emanuele Zucca, Bellinzona, Switzerland, Emilio Montserrat, Barcelona, Spain, Catherine Thieblemont, Lyon, France,Giovanni Martinelli, Milan, Italy, Peter Johnson, Southampton, UK, Italian Lymphoma Intergroup, Italy) 454 patients The aim of the study initially was to assess the therapeutic activity and safety of the combination of Chlorambucil and Rituximab in MALT lymphomas and to determine whether the addition of Rituximab to Chlorambucil will improve the outcome of MALT lymphoma in comparison to treatment with Chlorambucil alone. All the MALT lymphoma patients with localised disease at any site who do not respond to local therapy, the H.pylori-negative gastric lymphomas or those who failed antibiotic therapy will be eligible as well as those with disseminated or multifocal MALT lymphoma at any extranodal site. Because of the excellent and fast recruitment, after the accrual of 250 patients an amendment was introduced to add a third arm (namely, Rituximab alone). ASH 2009: poster presentation ASH 2010: oral and poster presentation Lugano Conference on Malignant Lymphoma 2011: poster presentation |
| ielsg | |
 IELSG 18 |
Retrospective international survey on primary effusion lymphomas (Chairpersons: A. Conconi, Novara, Italy, A. Carbone, Aviano, Italy, D. Knowles, New York, USA) 39 patients The Primary Effusion Lymphoma (PEL) is a B-cell neoplasm recently comprised in the WHO classification of lymphoproliferative disorders. PEL usually develops in severe immunocompromised patients and a strong etiologic relationship is recognized with the human herpesvirus type-8/Kaposi’s sarcoma-associated herpesvirus (HHV-8/KSHV). The lymphoma develops as a liquid-phase growth in the fluid-filled serous cavities of the body, tipically it displays an aggressive course. As in other rare entities the literature is based on isolated case-reports and no guidelines exhists on diagnosis and treatment. The aim of this study is to retrospectively study the clinico-patological features at diagnosis, the clinical course and general outcome in a large series of patients. The accrual has been closed and the pathology review is ongoing. ASH 2004: poster presentation Lugano Conference on Malignant Lymphoma 2005: poster presentation |
| ielsg | |
 IELSG 16 |
RT-PCR detection of the t(11;18) translocation as a predictor of outcome in extranodal marginal lymphoma of MALT type (Principal investigators: F. Bertoni, London, UK; E. Zucca, Bellinzona, Switzerland) The translocation t(11;18)(q21;21) is the most common and probably the most relevant genetic alteration in extranodal marginal zone B-cell lymphoma. The aim of this study is to evaluate the detection of this specific translocation as a predictive factor for response to anti-Helicobacter pylori antibiotic treatment in a large series of cases of primary gastric marginal zone B-cell lymphoma of MALT type. The laboratory design involves RNA extraction from paraffin-embedded tissue tumor sections and the presence of the translocation will be determined by RT-PCR using three different combinations of primers. Original article: Hematological Oncology, 2007 Dec; 25(4): 184–188 |
| ielsielsgg | |
 IELSG 15 |
Retrospective evaluation of primary breast lymphoma (Chairpersons: Giovanni Martinelli, Milan, Italy and Gail Ryan, Melbourne, Australia) 319 patients This is a retrospective survey of primary lymphoma of the breast, which comprises approximately 2% of all localized extranodal lymphomas and less than 0.5% of breast tumors. Review of the literature shows two apparently distinct clinical pathological groups, one, which affects young women frequently bilateral high grade lymphoma and the second group affects older women presenting with clinical features suggesting breast carcinoma. In this latter presentation the most common histology is the diffuse large B-cell type. However cases of low-grade lymphomas including some of MALT Hodgkin have also been reported. We hope this retrospective survey will improve our knowledge on this unusual presentation and possibly help generating new ideas for improving the treatment; indeed despite good local control, systemic failure occurs in at least half of the patients with breast lymphoma. ASCO 2005: poster presentation Original article: Annals of Oncology 2008; 19(2): 233-241 Original article: Annals of Oncology 2009 Dec; 20(12): 1993-9 |
| ielsg | |
 IELSG 14 |
Retrospective evaluation of primary bone lymphoma (Chairperson: David Christie, Tugun, Australia, Co-Chairpersons: Mary Gospodarowicz, Toronto, Canada; Bertrand Coiffier, Lyon, France; Giovanni Martinelli, Milan, Italy) 499 patients This is a retrospective study with the aim of getting information on the primary lymphoma of the bone, which constitutes less than 5% of primary extranodal lymphoma presentations. EHA 2007: poster presentation |
| IELSG | IELSG |
 IELSG 13 |
Prevalence of hepatitis C virus (HCV) infection among non-Hodgkin lymphoma (NHL) patients Feasibility study, involving a limited number of centers (Chairpersons: E. Zucca, A. Conconi, Bellinzona, Switzerland) 87 patients A growing body of evidence suggests that several human viruses can be involved in the multistep process of lymphomagenesis. The Hepatitis C virus (HCV), which is both hepato- and lymphotropic, has been associated with a variety of extrahepatic immuno-mediated conditions including monoclonal gammopthies and mixed cryoglobulinemia type II. Furthermore, a strong association of HCV infection and non-Hodgkin lymphoma has resulted in several studies from Italy, USA and some asian countries. In order to clarify whether HCV and/or HGV may have a role in the pathogenesis of lymphoproliferative disorders, the IELSG implemented this hospital-based case-control study. The pilot/feasibility study involves a limited number of centres from restricted geographical areas of Switzerland and Spain; patient enrolment has been closed and laboratory analyses have been done. A manuscript is in preparation. ESMO 2006: poster presentation Original article: Hematological Oncology 2011 September [Epub ahead of print] |
| ielsg | |
 IELSG 12 |
Chromosome 11q amplification in primary extranodal diffuse large B-cell lymphomas (Applicants and principal investigators: F. Bertoni, London, UK; Finbarr E. Cotter, MB, BS, FRCP, FRCPath, PhD. Co-author: E. Zucca, Bellinzona, Switzerland) This study deals with the chromosome 11q amplification in extranodal diffuse large B-cell lymphomas (DLBCL). About half of DLBCL rise at extranodal sites, most commonly within the gasto-intestinal tract. DNA and RNA samples from extranodal DLBCL will be analysed to identify - by specific DNA micro arrays - genes on chromosome 11, which may contribute to the pathogenesis of the disease. The aim of the study is to identify the genes over-expressed due to the 11q amplification, which could play an important role in 15-20% of DLBCL. This could help in possibly defining a third subgroup of DLBCL, in addition to patient presenting the t(14;18)(q32;q21) translocation and to the promiscuous group of rearrangements of the bcl6 at 3q27. Lugano Conference on Malignant Lymphoma 2005: poster presentation |
| ielsg | |
 IELSG 11 |
Retrospective evaluation of cutaneous B-cell lymphomas (Chairman: S. Cortelazzo, Bergamo, Italy) 287 patients This retrospective study was intended to design a prognostic score to identify different risk group in patients with Primary Cutaneous B-Cell Lymphoma (PCBCL). This group of lymphoproliferative diseases of the skin is, infact, quite heterogeneous with the exception of the diffuse large B-cell lymphoma of the leg. 175 PCBCL patients were retrospectively analysed. Lymphoma classification was performed according to the EORTC criteria. Multivariate analysis of clinical features identified 3 variables with significant unfavourable impact on survival: the histology of PCBCL of the leg, elevated LDH an the presence of B symptoms. Thus, considering these 3 variables, a prognostic score was established, considering 0 the favorable feature and >1 the unfavourable one. Application of this prognostic score to the assessable patients showed a statistically significant association with the patterns of response, relapse and survival, identifying different risk categories of patient with this lymphoproliferative disease. ASH 2001: poster presentation ASH 2008: poster presentation EHA 2009: poster presentation Original article: Annals of Hematology 2011 Apr; 90(4): 401-408 |
| ielsg | |
 IELSG 10 |
A phase II study of CHOP plus Rituximab, with intrathecal methotrexate followed by radiotherapy, in patients with primary testicular non-Hodgkin’s lymphoma (Chairman: A. Sarris, Athens, Greece) 64 patients This is a prospective study designed on the basis of the results provided by the IELSG 5 (Retrospective evaluation of primary testicular lymphomas), which suggested that proper therapy for this lymphoma location should include post-orchiectomy chemotherapy with antracycline containing regimens and controlateral scrotum irradiation plus intrathecal prophilaxis of CNS relapses. The study will prospectively test the feasibility and efficacy of the combined systemic chemotherapy (CHOP regimen) plus immunotherapy (Rituximab) in combination with intrathecal Methotrexate propholaxis and radiotherapy (scrotal controlateral irradiation for stage I disease, involved fields radiotherapy for stage II disease). The aim of this study is to provide adequate experience to propose this approach as the minimum standard treatment of diffuse large cell lymphoma of the testis. ASH 2006: oral presentation ASH 2006: poster presentation Lugano Conference on Malignant Lymphoma 2008: oral presentation EHA 2008: oral presentation Original article: Journal of Clinical Oncology 2011 July 2011;29(20): 2766-2772 |
| ielsg | |
 IELSG 9 |
Retrospective evaluation of primary mediastinal large B-cell lymphomas (Chairpersons: P. Zinzani, Bologna, M. Martelli, Roma, M. Bertini, Torino, Italy) 426 patients The mediastinal (thymic) is described as a distinct clinical pathologic entity in the new WHO classification of tumors of lymphoid tissues. The aim of the study was to collect a large series of cases to better understand the clinical behaviour of this tumor, which in a small series from single institutions appears to benefit from intensive aggressive chemotherapy combined with mediastinal irradiation. Moreover, in addition to the pathological review of most cases a immunophenotypic analysis of a large number of cases was planned. The final result of this study have been presented at the American Society of Hematology Meeting in December 2000 showing that primary mediastinal lymphoma is an aggressive but generally highly curable subentity where irradiation is almost always needed after chemotherapy. Two papers concerning clinical results and the molecular and immunophenotipic study have been published. |
| ielsg | |
 IELSG 8 |
Retrospective evaluation of primary intestinal lymphomas (Chairman: S. Cortelazzo, Bergamo, Italy) 280 patients Primary intestinal lymphoma (PIL) is a rare subtype of a NHL accounting for less than 1% of large bowel malignancies. In western countries the most frequent histologic type is represented by DLCL, followed by EATCL, IPSID, Burkitt and others. The PIL differs the many aspects from primary gastric lymphomas. Prognosis is usually worse and a different staging system score has been proposed (Lugano, 1993). As in other rare entities of NHL, the difficulty of collecting statistically significant series of patients makes it hard to identify prognostic categories and establish guidelines for optimal management. In this context, the IELSG has implemented a multicentric retrospective study with the aim of analysing the clinical outcome of a large and unselected series of patients and to investigate the value of possible prognostic factors. 547 consecutive patients were included in the study: 435 with gastric lymphoma and 112 with intestinal lymphoma. Multivariate analysis of prognostic parameters showed that the International Prognostic Index (IPI) was the strongest variable associated with clinical outcome. The best treatment in this retrospective series resulted of a combination of surgery and short-term chemotherapy, when compared to single modality treatment (5 year EFS 52%; VS 21%; P=0.0003). However, the clinical outcome was overall modest in this large series of patients, claiming for new treatment strategies. ASH 1999: oral communication Original article: British Journal of Haematology, 2002 July; 118(1): 218-228 |
| ielsg | |
 IELSG 7 |
Retrospective evaluation of central nervous system lymphomas (Chairmen: J.Y. Blay, Lyon, France, A. Ferreri, Milan, Italy) 378 patients Primary Central Nervous System Lymphomas (PCNSL) account for less than 1% of all NHL and represents a challenge for the oncologist for at least 2 reasons: - incidence has triplicated on the last decade not only in HIV patients but also in immunocompetent patients - therapeutic outcome in PCNSL is unsatisfactory and does not reflect the promising results obtained in other entities of NHL. Furthermore, due to the difficulty of collecting representative series of patients of this rare form of NHL, the optimal clinical management has not been defined yet. The IELSG conducted a retrospective analysis of primary CNS lymphoma (PCNSL) in order to identify clinical features which are relevant for prognosis and therapy. 378 HIV negative patients were collected from multi-institutionals. Retrospective analysis demonstrated that age, PS, LDH ratio and CSF protein level are significantly related to remission rate and are predictors of survival. Primary CT is superior to primary RT . Outcome was improved by the addition of HD-MTX to HD-AraC while IT-CHT was not related to survival. This study represents the largest series of patients with PCNSL and will constitute the background for future prospective clinical trials. ASH 2000: oral communication ASH 2000: poster presentation ASH 2000: poster presentation ECCO 2001: poster presentation First World Congress of Neuro-Oncology: oral communication Original article: Annals of Oncology, 2002; 13(4): 531-538 Original article: Neurology, 2002; 58(10): 1513-1520 Lugano Conference on Malignant Lymphoma 2002: poster presentation Original article: Journal of Clinical Oncology, January 2003;21(2): 266-272 Original article: British Journal of Haematology 2007 Aug;138(3):316-323 |
| ielsg | |
 IELSG 6 |
A phase II study to determine the clinical activity and safety of Rituximab (IDEC-C2B8) in marginal zone B-cell lymphomas (MZLs) (Chairpersons: A. Conconi, Bellinzona, Switzerland, C. Thieblemont, Lyon, France) 35 patients Marginal zone lymphoma (MZL) has been recognized as single entity only in recent times and the process of characterization is still ongoing. Therapeutic management of MZL is quite heterogeneous, ranging, as in other low grade lymphomas, from watchful waiting to more aggressive strategies. Single agent alkylating chemotherapy is the most often used approach. However no consensus exists on the best treatment modality. This study was a phase II trial to determine the activity and safety of monoclonal antibody anti-CD20 (Rituximab) in MZL. Both nodal and extranodal MZL were considered as well as splenic MZL. The trial enrolled 35 patients between January 2000 and May 2001. At a median follow up of 11.6 months the overall response rate was 73% with 15 CR and 10 PR. Nine patients had stable disease: Among them, 3 pts relapsed soon after treatment completion, 3 pts relapsed after CR and 3 pts relapsed after PR. Toxicity was mild with only one episode of grade 3 toxicity. This study demonstrated safety and efficacy of Rituximab as single agent treatment modality in MZL. ASCO 2001: poster presentation EHA 2001: poster presentation ASH 2001: oral communication ASCO 2002: poster presentation Lugano Conference on Malignant Lymphoma 2002: poster presentation Original article: Blood 2003; 102(8): 2741-2745 |
| ielsg | |
 IELSG 5 |
Retrospective evaluation of primary testicular lymphomas (Chairpersons: M. Gospodarowicz, Toronto, Canada, T. Mughal, Manchester, U.K., U. Vitolo, Torino, Italy) 373 patients This was a retrospective study with aim of getting information on a very rare disease presentation from the analysis of a large number of cases. This multicentre retrospective analysis of 373 cases is by far the largest series of testicular lymphoma patients ever reported. The study confirms the importance of extranodal sites of relapse, particularly the CNS, and suggests that proper treatment should include post-orchiectomy chemotherapy (with an anthracycline-containing regimen) and controlateral scrotum irradiation plus some prophylaxis of CNS relapses. Final results have been published by the Journal of Clinical Oncology. ASH 2000: poster presentation AUA 2001: podium presentation Original article: Journal of Clinical Oncology, January 2003; 21(1): 20-27 |
| ielsg | |
 IELSG 4 |
Prospective randomized trial of chemotherapy vs chemotherapy plus irradiation in diffuse large-cell gastric lymphoma (Chairman: G. Martinelli, Milano, Italy) 54 patients This randomized study has been designed to ascertain whether the addition of radiotherapy can improve the results obtainable with chemotherapy alone in localized high-grade gastric lymphomas. Original article: Leukemia and Lymphoma 2009 Jun; 50(6): 925-31 |
| ielsg | |
 IELSG 3 |
Randomized trial of observation vs chlorambucil after anti-helicobacter therapy in low-grade gastric lymphoma (Chairmen: E. Zucca, E. Roggero, Bellinzona, Switzerland) 190 patients This is the LY03 study originally launched by the UKLG/BNLI (United Kingdom Lymphoma Group and British National Lymphoma Investigation) to study whether the addition of Clorambucil after anti-helicobacter therapy is of any benefit in low grade gastric MALT lymphoma. The study was carried out by the IELSG in co-operation with the GELA (Groupe d'Étude des Lymphomes de l'Adulte) and was prematurely closed due to the slow accrual. However, approximately 200 patients have been enrolled and this is probably the largest series of antibiotic-treated gastric MALT lymphoma prospectively followed-up. Preliminary analysis of the lymphoma response to antibiotic has been presented at ASCO 2000. The study confirmed that eradication of H. pylori can induce histological regression in the majority of localised low grade lymphoma MALT lymphoma of the stomach. Preliminary results of a molecular follow-up (performed by polymerase chain reaction targeted to the immunoglobulin heavy chain genes to assess the molecular residual disease in a subset of patients) have been published in Blood (Bertoni et al., 2002), showing that approximately half of the patient with an histological regression can achieve a continuous molecular remission after antibiotic therapy. However, given the indolent nature of MALT lymphomas a longer follow-up is needed before any definitive conclusion. ASCO 1999: oral communication Lugano Conference on Malignant Lymphoma 1999: oral presentation ASCO 2000: oral communication EHA 2001: oral communication ASH 2001: oral communication Original article: Blood, 2002; 99(7): 2541-2544 Lugano Conference on Malignant Lymphoma 2005: poster presentation - oral presentation Original article: British Journal of Haematology, 2009Feb;144(3):367-75 |
| ielsg | |
 IELSG 2 |
Retrospective analysis of patients with primary localized diffuse large B-cell lymphoma of the stomach
450 patients This study was conducted to assess the value of the international prognostic index (IPI) in predicting the outcome of patients with primary gastric lymphoma. The final results of the study (312 patients analysed from 9 institutions) have been published in Annals of Oncology (Cortelazzo et al., 1999) and showed that a stage modified international prognostic index is able to predict the clinical outcome in patients with primary diffuse large cell lymphoma of the stomach. Lugano Conference on Malignant Lymphoma 1999: poster presentation ASH 1998: oral communication Original article: Annals of Oncology, 1999; 10(12): 1433-1440 |
| ielsg | |
 IELSG 1 |
Retrospective evaluation of low-grade MALT lymphoma primarily arising at non-gastric sites 369 patients This study was designed in the second half of the 90' and officially activated as the first IELSG trial on February 1998. Marginal zone lymphomas account for about 10% of all NHLs and the best studied entity is the localized gastric MALT lymphoma. On the contrary, information concerning non gastric MALT lymphomas are poor and often condradictory, mainly due to limited cohort of patients. The aim of the study was to describe the clinical and pathological characteristics of a large series of patients with a proven diagnosis of marginal zone non-Hodgkin's lymphoma arisig at non gastric sites. The IELSG studied 369 patients from 22 centres worldwide. Histologic diagnosis of 292 was reviewed by a panel of 21 pathologists. A high proportion of patients were treated with primary surgery and/or radiotherapy. Our data confirm an overall good prognosis for this subtype of NHL even in the presence of disseminated disease. The manuscript on this study has been prepublished on line as Blood First Edition Paper (November 27, 2002; DOI 10.1182/blood-2002-04-1279) ASH 1999 ESMO 2000: oral communication Original article: Blood 2003; 101(7): 2489-2495 |